Hajek R, Pour L, Ozcan M, et al. - In individuals with relapsed or relapsed/refractory multiple myeloma who had received 1–3 prior therapies, researchers assessed ibrutinib, a once-daily inhibitor of Bruton’s tyrosine kinase, combined with bortezomib and dexamethasone. Seventy-six individuals were recruited in phase 2, single-arm, open-label, multicentre study. Seventy-four received ≥ 1 dose of study treatment. According to the findings, clinical responses were elicited by Ibrutinib combined with bortezomib and dexamethasone. Data reported that median progression-free survival (PFS) was 8.5 months after median follow-up of 19.6 months. Efficacy assessments conducted at the potential restart of enrolment, however, revealed that the targeted PFS could not be reached with additional patient enrolment, and the analysis was discontinued.